<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35616813</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>5189</StartPage><EndPage>5199</EndPage><MedlinePgn>5189-5199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06131-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the association between the use of common medications on hypertension, hyperlipidemia, diabetes, and the risk of amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, EMBASE, OVID, and Web of Science were searched systematically until December 2021 for studies quantitatively investigating the effect of medications on hypertension, hyperlipidemia, and diabetes on the risk of ALS. We conducted a fixed-effects model or random-effects meta-analysis to calculate the summary ORs (odds ratios) and 95%CIs (confidence intervals).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Regular intake of angiotensin-converting enzyme inhibitors (ACEIs) (OR: 0.81, 95%CI: 0.74, 0.89), beta-blockers (OR: 0.82, 95%CI: 0.76, 0.90), calcium-channel blockers (CCBs) (OR: 0.85, 95%CI: 0.79, 0.93), or diuretics (OR: 0.87, 95%CI: 0.81, 0.93) was inversely associated with the incidence of ALS. There was no significant association between statin use and risk of ALS (OR: 0.92, 95%CI: 0.83, 1.03). Metformin (OR: 0.83, 95%CI: 0.75, 0.93) and sulfonylureas (OR: 0.79, 95%CI:0.71, 0.89) use could significantly reduce the risk of ALS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Regular use of anti-hypertensive drugs and anti-diabetes including ACEIs, beta-blockers, CCBs, diuretics, metformin, and sulfonylureas could protect against the incidence of ALS. No significant association between anti-hyperlipidemia drug use and risk of ALS was revealed. Regular medications for hypertension, hyperlipidemia, and diabetes should be recommended regardless of the diagnosis of ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4046-8439</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, 100730, China. hunan_pumch@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004232">Diuretics</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Hyperlipidemia</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Medications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35616813</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06131-7</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06131-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942&#x2013;955</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J et al (2007) Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 64(4):522&#x2013;528</Citation><ArticleIdList><ArticleId IdType="pubmed">17420313</ArticleId><ArticleId IdType="doi">10.1001/archneur.64.4.522</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA et al (2016) A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry 87(12):1361&#x2013;1367</Citation><ArticleIdList><ArticleId IdType="pubmed">27378085</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2015-312908</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 32(5):771&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pubmed">31361627</ArticleId><ArticleId IdType="pmc">6735526</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Silva JP et al (2020) Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev 111:1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">31917162</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2019.12.032</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F et al (2019) Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis. Acta Neurol Scand 139(5):438&#x2013;445</Citation><ArticleIdList><ArticleId IdType="pubmed">30712314</ArticleId><ArticleId IdType="doi">10.1111/ane.13073</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhiney MC et al (2009) Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 80(10):1146&#x2013;1149</Citation><ArticleIdList><ArticleId IdType="pubmed">19762902</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2008.163246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabkin JG et al (2015) Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 16(3&#x2013;4):265&#x2013;273</Citation><ArticleIdList><ArticleId IdType="pubmed">25482273</ArticleId><ArticleId IdType="doi">10.3109/21678421.2014.980428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP (2020) Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener 21(1&#x2013;2):140&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pubmed">31450993</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1655060</ArticleId></ArticleIdList></Reference><Reference><Citation>(2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7): 505&#x2013;512</Citation></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012(3):Cd001447</Citation><ArticleIdList><ArticleId IdType="pmc">7055506</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C et al (2017) Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener 18(7&#x2013;8):590&#x2013;597</Citation><ArticleIdList><ArticleId IdType="pubmed">28616937</ArticleId><ArticleId IdType="doi">10.1080/21678421.2017.1336560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA et al (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72(8):905&#x2013;911</Citation><ArticleIdList><ArticleId IdType="pubmed">26030836</ArticleId><ArticleId IdType="pmc">4975611</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C et al (2012) Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13(2):194&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">21913867</ArticleId><ArticleId IdType="doi">10.3109/17482968.2011.610110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J et al (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25(6):861&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">29512869</ArticleId><ArticleId IdType="doi">10.1111/ene.13620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian L et al (2019) Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in China. J Clin Neurosci 66:12&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">31155341</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2019.05.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM et al (2018) Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener 19(7&#x2013;8):538&#x2013;546</Citation><ArticleIdList><ArticleId IdType="pubmed">31112080</ArticleId><ArticleId IdType="doi">10.1080/21678421.2018.1511731</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M et al (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261(10):1949&#x2013;1956</Citation><ArticleIdList><ArticleId IdType="pubmed">25059395</ArticleId><ArticleId IdType="doi">10.1007/s00415-014-7445-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso S et al (2009) Insulin is a two-edged knife on the brain. J Alzheimers Dis 18(3):483&#x2013;507</Citation><ArticleIdList><ArticleId IdType="pubmed">19542630</ArticleId><ArticleId IdType="doi">10.3233/JAD-2009-1155</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H et al (2013) Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 33(3):347&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">23271639</ArticleId><ArticleId IdType="doi">10.1007/s10571-012-9900-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RM et al (2020) Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener 21(3&#x2013;4):235&#x2013;245</Citation><ArticleIdList><ArticleId IdType="pubmed">31684770</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1682613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700</Citation><ArticleIdList><ArticleId IdType="pubmed">19622552</ArticleId><ArticleId IdType="pmc">2714672</ArticleId><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId></ArticleIdList></Reference><Reference><Citation>Skajaa N et al (2021) Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology</Citation></Reference><Reference><Citation>Mariosa D et al (2020) Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol 27(6):1010&#x2013;1016</Citation><ArticleIdList><ArticleId IdType="pubmed">32097525</ArticleId><ArticleId IdType="doi">10.1111/ene.14190</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrandell-Haro G et al (2020) Statin therapy and risk of Alzheimer&#x2019;s and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 6(1):e12108</Citation></Reference><Reference><Citation>Schumacher J et al (2020) Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol 27(8):1405&#x2013;1414</Citation><ArticleIdList><ArticleId IdType="pubmed">32396653</ArticleId><ArticleId IdType="doi">10.1111/ene.14300</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann K et al (2020) Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol 267(7):2130&#x2013;2141</Citation><ArticleIdList><ArticleId IdType="pubmed">32266542</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09799-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond L et al (2020) Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration. Behav Sci (Basel) 10(1)</Citation></Reference><Reference><Citation>Franchi C et al (2016) Angiotensin-converting enzyme inhibitors and motor neuron disease: an unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener 17(5&#x2013;6):385&#x2013;388</Citation><ArticleIdList><ArticleId IdType="pubmed">26913547</ArticleId><ArticleId IdType="doi">10.3109/21678421.2016.1143515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin FC et al (2015) Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 72(1):40&#x2013;48</Citation><ArticleIdList><ArticleId IdType="pubmed">25383557</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3367</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi M et al (2008) Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9(6):369&#x2013;374</Citation><ArticleIdList><ArticleId IdType="pubmed">18608098</ArticleId><ArticleId IdType="doi">10.1080/17482960802163614</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden D, Diehl RR, Berlit P (1998) Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol 109(5):387&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">9851294</ArticleId><ArticleId IdType="doi">10.1016/S0924-980X(98)00035-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Scelsa SN, Khan I (2000) Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol 43(4):224&#x2013;227</Citation><ArticleIdList><ArticleId IdType="pubmed">10828653</ArticleId><ArticleId IdType="doi">10.1159/000008180</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C et al (1991) Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol 48(3):283&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">2001186</ArticleId><ArticleId IdType="doi">10.1001/archneur.1991.00530150051017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M et al (2021) Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci 421:117292</Citation><ArticleIdList><ArticleId IdType="pubmed">33423011</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.117292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer&#x2019;s disease? Lancet Neurol 6(4):373&#x2013;378</Citation><ArticleIdList><ArticleId IdType="pubmed">17362841</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(07)70077-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 10(3):253&#x2013;263</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravati A et al (1999) Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol 373(1):21&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">10408248</ArticleId><ArticleId IdType="doi">10.1016/S0014-2999(99)00211-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira ML et al (1993) Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun 19(3):173&#x2013;181</Citation><ArticleIdList><ArticleId IdType="pubmed">8244086</ArticleId><ArticleId IdType="doi">10.3109/10715769309111600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengul G et al (2011) Neuroprotective effect of ACE inhibitors in glutamate - induced neurotoxicity: rat neuron culture study. Turk Neurosurg 21(3):367&#x2013;371</Citation><ArticleIdList><ArticleId IdType="pubmed">21845573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H et al (2011) Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 173(6):595&#x2013;602</Citation><ArticleIdList><ArticleId IdType="pubmed">21335424</ArticleId><ArticleId IdType="pmc">3105261</ArticleId><ArticleId IdType="doi">10.1093/aje/kwq416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohrui T et al (2004) Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63(7):1324&#x2013;1325</Citation><ArticleIdList><ArticleId IdType="pubmed">15477567</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000140705.23869.E9</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon KA et al (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson&#x2019;s disease. Aust N Z J Med 30(1):48&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">10800878</ArticleId><ArticleId IdType="doi">10.1111/j.1445-5994.2000.tb01054.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY et al (2020) Effects of &#x3b2;-adrenergic blockade on metabolic and inflammatory responses in a rat model of ischemic stroke. Cells 9(6)</Citation></Reference><Reference><Citation>Leal SS, Gomes CM (2015) Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Front Cell Neurosci 9:225</Citation><ArticleIdList><ArticleId IdType="pubmed">26136661</ArticleId><ArticleId IdType="pmc">4468822</ArticleId><ArticleId IdType="doi">10.3389/fncel.2015.00225</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG et al (1996) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6(2):101&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">8664560</ArticleId><ArticleId IdType="doi">10.1016/0960-8966(95)00024-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG et al (1996) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19(4):511&#x2013;515</Citation><ArticleIdList><ArticleId IdType="pubmed">8622731</ArticleId><ArticleId IdType="doi">10.1002/mus.880190405</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J et al (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258(4):613&#x2013;617</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R et al (2015) The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 16(5&#x2013;6):359&#x2013;365</Citation><ArticleIdList><ArticleId IdType="pubmed">26121273</ArticleId><ArticleId IdType="doi">10.3109/21678421.2015.1047454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S et al (2019) Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 85(4):470&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pubmed">30723964</ArticleId><ArticleId IdType="pmc">6450729</ArticleId><ArticleId IdType="doi">10.1002/ana.25431</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltowski J (2010) Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit 16(3):Ra73-78</Citation><ArticleIdList><ArticleId IdType="pubmed">20190699</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards IR, Star K, Kiuru A (2007) Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 30(6):515&#x2013;525</Citation><ArticleIdList><ArticleId IdType="pubmed">17536877</ArticleId><ArticleId IdType="doi">10.2165/00002018-200730060-00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannarong T, Ungprasert P (2020) Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurol Neurosurg 199:106248</Citation><ArticleIdList><ArticleId IdType="pubmed">33031990</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2020.106248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R et al (2021) The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol Sci 42(4):1377&#x2013;1387</Citation><ArticleIdList><ArticleId IdType="pubmed">33544228</ArticleId><ArticleId IdType="pmc">7955983</ArticleId><ArticleId IdType="doi">10.1007/s10072-021-05099-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L et al (2022) Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci Rep 12(1):2544</Citation><ArticleIdList><ArticleId IdType="pubmed">35169211</ArticleId><ArticleId IdType="pmc">8847454</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-06463-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T et al (2020) Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci U S A 117(31):18591&#x2013;18599</Citation><ArticleIdList><ArticleId IdType="pubmed">32690681</ArticleId><ArticleId IdType="pmc">7414156</ArticleId><ArticleId IdType="doi">10.1073/pnas.2005748117</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J et al (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS ONE 13(3):e0193031</Citation><ArticleIdList><ArticleId IdType="pubmed">29513760</ArticleId><ArticleId IdType="pmc">5841739</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0193031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D et al (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 22(11):1436&#x2013;1442</Citation><ArticleIdList><ArticleId IdType="pubmed">25600257</ArticleId><ArticleId IdType="pmc">4506907</ArticleId><ArticleId IdType="doi">10.1111/ene.12632</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K et al (2019) TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest 129(9):3578&#x2013;3593</Citation><ArticleIdList><ArticleId IdType="pubmed">31355778</ArticleId><ArticleId IdType="pmc">6715357</ArticleId><ArticleId IdType="doi">10.1172/JCI124481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>